A method to increase tetramer staining efficiency of CD8+ T cells with MHC-peptide complexes: Therapeutic applications in monitoring cytotoxic T lymphocyte activity during hepatitis B and C treatment

Journal of Immunological Methods

Volumn 285, Issue 1, 2004, Pages 71-87

  Tsai, Sun Lung ^a   Lee, Tzong Hsien ^b   Chien, Rong Nan ^b   Liao, Shuen Kuei ^b   Lin, Chen Lung ^c   Kuo, George C ^d   Liaw, Yun Fan ^b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c QUEEN MARY HOSPITAL   (Hong Kong)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antiviral therapy; Cytotoxic T lymphocyte; Hepatitis B virus; Hepatitis C virus; Tetramer assay

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CD8 ANTIGEN; HLA A2 ANTIGEN; LAMIVUDINE; RIBAVIRIN; TETRAMER; THYMOSIN ALPHA1;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 1042292703     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2003.11.005     Document Type: Article

References (59)

1. Adorini L., Appella E., Doria G., Nagy Z.A. Mechanisms influencing the immunodominance of T cell determinants. J. Exp. Med. 168:1988;2091.
2. Altman J.D., Moss P.A.H., Goulder P.J.R., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., McMichael A.J., Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94.
3. Battegay M., Fikes J., Di-Bisceglie A.M., Wentworth P.A., Sette A., Celis E., Ching W.M., Grakoui A., Rice C.M., Kurokohchi K.l. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J. Virol. 69:1995;2462.
4. Bertoletti A., Maini M.K. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr. Opin. Immunol. 12:2000;403.
5. Boni C., Bertoletti A., Penna A., Cavalli A., Pilli M., Urbani S., Scognamiglio P., Boehme R., Panebianco R., Fiaccadori F. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest. 102:1998;968.
6. Boni C., Penna A., Ogg G.S., Bertoletti A., Pilli M., Cavallo C., Cavalli A., Urbani S., Boehme R., Panebianco R., Fiaccadori F., Ferrari C. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology. 33:2001;963.
7. Cerny A., Mc-Hutchison J.G., Pasquinelli C., Brown M.E., Brothers M.A., Grabscheid B., Fowler P., Houghton M., Chisari F.V. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J. Clin. Invest. 95:1995;521.
8. Chang K.M., Rehermann B., Mc-Hutchison J.G., Pasquinelli C., Southwood S., Sette A., Chisari F.V. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J. Clin. Invest. 100:1997;2376.
9. Chen P.J., Lin M.H., Tai K.F., Liu P.C., Lin C.J., Chen D.S. The Taiwanese hepatitis C virus genome: sequence determination and mapping the 5′ termini of viral genomic and antigenomic RNA. Virology. 188:1992;102.
10. Chien R.N., Liaw Y.F., Chen T.C., Yeh C.T., Sheen I.S. Efficacy of thymosin α1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 27:1998;1383-1387.
11. Chisari F.V. Viruses, immunity, and cancer: lessons from hepatitis B. Am. J. Pathol. 156:2000;1118.
12. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13:1995;29.
13. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., Houghton M., Parham P., Walker C.M. Analysis of a successful immune response against hepatitis C virus. Immunity. 10:1999;439.
14. Desmyter J., Ray M.B., De-Groot J., Bradburne A.F., Desmet V.J., Edy V.G., Billiau A., De-Somer P. Administration of human fibroblast interferon in chronic hepatitis B infection. Lancet. ii:1976;645.
15. Dienstag J.L., Schiff E.R., Wright T.L., Perillo R.P., Hann H.W.L., Goodman Z., Crowther L., Condreay L.D., Woessner M., Rubin M.et al. Lamivudine as initial treatment for chronic hepatitis B. N. Engl. J. Med. 341:1999;1256.
16. Doherty P.C., Christensen J.P. Accessing complexity: the dynamics of virus-specific T cell responses. Annu. Rev. Immunol. 18:2000;561.
17. Doherty P.C., Belz G.T., Flynn K.J. The continuing revolution in virus-specific CD8+ T cell-mediated immunity. Immunologist. 6:1998;173.
18. Goepfert P.A., Bansal A., Edwards B.H., Ritter G.D., Tellez I., McPherson S.A., Sabbaj S., Mulligan M.J. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferion. J. Virol. 74:2000;10249.
19. Greenberg H.B., Pollard R.B., Lutwick L.I., Gregory P.B., Robinson W.S., Merigan T.C. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N. Engl. J. Med. 295:1976;517.
20. He X.S., Rehermann B., López-Labrador F.X., Boisvert J., Cheung R., Humm J., Wedemeyer H., Berenguer M., Wright T.L., Davis M.M., Greenberg H.B. Quantitative analysis of hepatitis C virus-specific CD8+ T cells in peripheral blood and liver using peptide-MHC tetramers. Proc. Natl. Acad. Sci. U. S. A. 96:1999;5692.
21. Hoofnagle J.H., Di-Bisceglie A.M. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:1997;347.
22. Jonas M.M., Kelley D.A., Mizerski J., Baclia I.B., Areias J.A., Schwarz K.B., Little N.R., Greensmith M.J., Gardner S.D., Bell M.S.et al. Clinical trial of lamivudine in children with chronic hepatitis B. N. Engl. J. Med. 346:2002;1706.
23. Kelleher A.D., Rowland-Jones S.L. Functions of tetramer-stained HIV-specific CD4(+) and CD8(+) T cells. Curr. Opin. Immunol. 12:2000;370.
24. Koshy R., Inchauspé G. Evaluation of hepatitis C virus protein epitopes for vaccine development. Trends Biotech. 14:1996;364.
25. Lai C.L., Chien R.H., Leung N.W.Y., Chang T.T., Guan R., Tai D.I., Ng K.Y., Wu P.C., Dent J.C., Barber J.et al. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:1998;61.
26. Lalvani A., Brookes R., Hambleton S., Britton W.J., Hill A.V., McMichael A.J. Rapid effector function in CD8+ memory T cells. J. Exp. Med. 186:1997;859.
27. Lauer G.M., Walker B.D. Hepatitis C virus infection. N. Engl. J. Med. 345:2001;41.
28. Lauer G.M., Nguyen T.N., Day C.L., Robbins G.K., Flynn T., McGowan K., Rosenberg E.S., Lucas M., Klenerman P., Chung R.T., Walker B.D. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J. Virol. 76:2002;2817.
29. +-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J. Virol. 76:2002;6104.
30. Lee W.M. Hepatitis B virus infection. N. Engl. J. Med. 337:1997;1733.
31. Lee T.H., Chuang Y.L., Tsai S.L., Liaw Y.F. Effects of lamivudine on the hepatitis B virus specific CD8+ cytotoxic T lymphocyte response via peptide-MHC tetrameric complexes assay. Lett. Pept. Sci. 8:2002;179.
32. Lefkovits I., Waldmann H. Limiting dilution analysis of the cells of immune system I. The clonal basis of the immune response. Immunol. Today. 5:1984;265.
33. Liaw Y.F., Tsai S.L. Pathogenesis and clinical significance of spontaneous exacerbations and remissions in chronic hepatitis B virus infection. Viral Hepat. Rev. 3:1997;143.
34. Liaw Y.F., Leung N.W.Y., Chang T.T., Guan R., Tai D.I., Ng K.Y., Chien R.N., Dent J., Roman L., Edmundson S. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology. 119:2000;172.
35. Livingstone A.M., Fathman C.G. The structure of T-cell epitopes. Annu. Rev. Immunol. 5:1987;477.
36. Maini M.K., Casorti G., Dellabona P., Wack A., Beverley P.C.L. T-cell clonality in immune responses. Immunol. Today. 20:1999;262.
37. Maini M.K., Boni C., Ogg G.S., King A.S., Reignat S., Lee C.Y., Larrubia J.R., Webster G.J.M., McMichael A.J., Ferrari C., Williams R., vergani D., Bertoletti A. Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology. 117:1999;1386.
38. Maini M.K., Boni C., Lee C.K., Larrubia J.R., Reignat S., Ogg G.S., King A.S., Herberg J., Gilson R., Alisa A., Williams R., vergani D., Nauomov N.V., Ferrari C., Bertoletti A. The role of virus-specific CD8+ cell in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 191:2000;1269.
39. McMichael A.J., O'Callaghan C.A. A new look at T cells. J. Exp. Med. 187:1998;1367-1371.
40. Murali-Krishna K., Altman J.D., Suresh M., Sourdive D.J., Zajac A.J., Miller J.D., Slansky J., Ahmed R. Counting antigen-specific CD8 T cell: a reevaluation of bystander activation during viral infection. Immunity. 8:1998;177.
41. Nepom G.T., Buckner J.H., Novak E.J., Reichstetter S., Reijonen H., Gebe J., Wang R., Swanson E., Kwok W.W. HLA class II tetramers: tools for direct analysis antigen-specific CD4+ T cells. Arthritis Rheum. 46:2002;5.
42. Ogg G.S., Xin J., Bonhoeffer S., Dunber P.R., Nowak M.A., Monard S., Segal J.P., Cao Y., Rowland-Jones S.L., Cerundolo V.et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma viral RNA load. Science. 279:1998;2103.
43. Purcell R.H. Hepatitis viruses: changing patterns of human disease. Proc. Natl. Acad. Sci. U. S. A. 91:1994;2401.
44. Rehermann B. Interaction between the hepatitis C virus and the immune system. Semin. Liver Dis. 20:2000;127.
45. Rehermann B., Fowler P., Sidney J., Person J., Redeker A., Brown M., Moss B., Sette A., Chisari F.V. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J. Exp. Med. 181:1995;1047.
46. Rehermann B., Chang K.M., McHutchison J., Kokka R., Houghton M., Rice C.M., Chisari F.V. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J. Virol. 70:1996;7092.
47. Rehermann B., Chang K.M., McHutchison J.G., Kokka R., Houghton M., Chisari F.V. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J. Clin. Invest. 98:1996;1432.
48. Sharrock C.E., Kaminski E., Man S. Limiting dilution analysis of human T cells: a useful clinical tool. Immunol. Today. 11:1990;281.
49. Sherman K.E., Sjogren M., Creager R.L., Damiano M.A., Freeman S., Lewey S., Davis D., Root S., Weber F.L., Ishak K.G. Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology. 27:1998;1128.
50. Tan L.C., Gudgeon N., Annels N.E., Hansasuta P., O'Callaghan C.A., Rowland-Jones S., McMichael A.J., Rickinson A.B., Callan M.F. A reevaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J. Immunol. 162:1999;1827.
51. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 126:1981;1614.
52. Tsai S.L., Chen P.J., Lai M.Y., Yang P.M., Sung J.L., Huang J.H., Hwang L.H., Chang T.H., Chen D.S. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. J. Clin. Invest. 89:1992;87.
53. Tsai S.L., Liaw Y.F., Chen M.H., Huang C.Y., Kuo G.C. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology. 25:1997;449.
54. Tsai S.L., Chen Y.M., Chen M.H., Huang C.Y., Sheen I.S., Yeh C.T., Huang J.H., Kuo G.C., Liaw Y.F. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology. 115:1998;954.
55. Tsai S.L., Sheen I.S., Chien R.N., Chu C.M., Huang H.C., Chuang Y.L., Lee T.H., Liao S.K., Lin C.L., Kuo G.C., Liaw Y.F. Activation of Th1 immunity is a common immune mechanism for successful treatment of hepatitis B and C: tetramer assay and therapeutc implications. J. Biomed. Sci. 10:2003;120.
56. Von-Andrian U.H., Mackay C.R. T-cell function and migration: two sides of the same coin. N. Engl. J. Med. 343:2000;1021.
57. Wedemeyer H., He X.S., Nascimbeni M., Davis A.R., Greenberg H.B., Hoofnagle J.H., Liang T.J., Alter H., Rehermann B. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J. Immunol. 169:2002;3447.
58. Wesselborg S., Janssen O., kabelitz D. Induction of activation-deriven death (apoptosis) in activated but not resting peripheral blood T cells. J. Immunol. 150:1991;3438.
59. Zinkernagel R.M. On cross-priming of MHC class I-specific CTL: rule or exception? Eur. J. Immunol. 32:2002;2385.